Topical 5% imiquimod for the therapy of actinic cheilitis

Smith, Kathleen J.; Germain, Marguerite; Yeager, Josef; Skelton, Henry G.

doi:10.1067/mjd.2002.126266

Cited by 78 publications

(70 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…82 In 2002, there was a review of 15 patients (3 women and 12 men) who applied imiquimod 3 times per week for 4-6 weeks. All of the patients showed clinical clearing of their AC at 4 weeks after discontinuation of treatment.…”

Section: Cutaneous T-cell Lymphoma (Ctcl)mentioning

confidence: 99%

“…Nine patients were followed up for 3 months or more and had no evidence of recurrence. 82 Stucco Keratosis (SK) Stucco keratosis (SK) is a skin disorder usually found on the lower limbs of elderly people. One study reported a 75-year-old man with lesions all over his body who was treated with imiquimod 3 times per week for 5 weeks.…”

Section: Cutaneous T-cell Lymphoma (Ctcl)mentioning

confidence: 99%

See 1 more Smart Citation

Viral and Nonviral Uses of Imiquimod: A Review

2004

View full text Add to dashboard Cite

show abstract

Section: Cutaneous T-cell Lymphoma (Ctcl)mentioning

confidence: 99%

Section: Cutaneous T-cell Lymphoma (Ctcl)mentioning

confidence: 99%

Viral and Nonviral Uses of Imiquimod: A Review

2004

View full text Add to dashboard Cite

show abstract

“…88,89 Imiquimod has also been explored for AC; despite Canadian labelling that restricts use of 3.75% and 5% imiquimod on the lips, this approach is common in clinical practice. 90 If available, laser resurfacing of the lip and laser-activated PDT are other field-directed approaches with good short-and long-term clearance and good to excellent cosmesis. 58,76,91,92 Electrodesiccation, which may be more widely accessible, offers similar short-term outcomes to those of laser resurfacing.…”

Section: Treatment Options For Acmentioning

confidence: 99%

Non-melanoma Skin Cancer in Canada Chapter 3: Management of Actinic Keratoses

et al. 2015

View full text Add to dashboard Cite

Background Actinic keratosis (AK) and cheilitis (AC) are lesions that develop on photodamaged skin and may progress to form invasive squamous cell carcinomas (SCCs). Objective To provide guidance to Canadian health care practitioners regarding management of AKs and ACs. Methods Literature searches and development of graded recommendations were carried out as discussed in the accompanying introduction (chapter 1 of the NMSC guidelines). Results Treatment of AKs allows for secondary prevention of skin cancer in sun-damaged skin. Because it is impossible to predict whether a given AK will regress, persist, or progress, AKs should ideally be treated. This chapter discusses options for the management of AKs and ACs. Conclusions Treatment options include surgical removal, topical treatment, and photodynamic therapy. Combined modalities may be used in case of inadequate response. AKs are particularly common following the longterm immunosuppression in organ transplant patients, who should be monitored frequently to identify emerging lesions that require surgery.

show abstract

“…80 However, to our knowledge, histologic clearance of SC with imiquimod has not been shown, raising concern for the ability of this drug to eradicate the disease at the microscopic level. 81 Reduction in the degree of dysplasia with imiquimod alone has been shown in a small study, but larger clinical trials with long-term data would be reassuring. 82 Aphthous ulcers are a potential side effect.…”

Section: Medical Approachesmentioning

confidence: 96%